ES2773317T3 - Método de tratamiento de estados del ojo con un DARPin anti-VEGF - Google Patents

Método de tratamiento de estados del ojo con un DARPin anti-VEGF Download PDF

Info

Publication number
ES2773317T3
ES2773317T3 ES14802544T ES14802544T ES2773317T3 ES 2773317 T3 ES2773317 T3 ES 2773317T3 ES 14802544 T ES14802544 T ES 14802544T ES 14802544 T ES14802544 T ES 14802544T ES 2773317 T3 ES2773317 T3 ES 2773317T3
Authority
ES
Spain
Prior art keywords
binding protein
seq
amino acid
repeat
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14802544T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Hohman
Janet Cheetham
Scott Whitcup
Erik Lippa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2773317T3 publication Critical patent/ES2773317T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES14802544T 2013-11-05 2014-11-04 Método de tratamiento de estados del ojo con un DARPin anti-VEGF Active ES2773317T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900246P 2013-11-05 2013-11-05
US201462016620P 2014-06-24 2014-06-24
PCT/US2014/063951 WO2015069668A1 (en) 2013-11-05 2014-11-04 Method of treating conditions of the eye with an anti-vegf darpin

Publications (1)

Publication Number Publication Date
ES2773317T3 true ES2773317T3 (es) 2020-07-10

Family

ID=51947485

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14802544T Active ES2773317T3 (es) 2013-11-05 2014-11-04 Método de tratamiento de estados del ojo con un DARPin anti-VEGF

Country Status (14)

Country Link
US (4) US20150126458A1 (OSRAM)
EP (2) EP3065761B1 (OSRAM)
JP (3) JP2016536369A (OSRAM)
KR (1) KR20160070164A (OSRAM)
CN (1) CN105960247A (OSRAM)
AU (2) AU2014346921A1 (OSRAM)
CA (1) CA2927012A1 (OSRAM)
DK (1) DK3065761T3 (OSRAM)
ES (1) ES2773317T3 (OSRAM)
HU (1) HUE047910T2 (OSRAM)
PL (1) PL3065761T3 (OSRAM)
PT (1) PT3065761T (OSRAM)
TW (1) TWI729970B (OSRAM)
WO (1) WO2015069668A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
US10568934B2 (en) 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy
BR112020022610A2 (pt) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações
JP7695187B2 (ja) 2018-09-24 2025-06-18 アイポイント ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
BR112021024231A2 (pt) * 2019-06-04 2022-04-26 Molecular Partners Ag Proteínas de ligação fap recombinantes e uso da mesma
EP4225796A4 (en) 2020-10-07 2024-11-13 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease
WO2022074623A1 (en) 2020-10-08 2022-04-14 Notal Vision Ltd. Oct guided therapy
CN114075290B (zh) * 2022-01-20 2022-04-19 南京鼓楼医院 Cd40靶向结合蛋白、其编码核酸以及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0011407B8 (pt) 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
ES2362386T3 (es) 2007-06-21 2011-07-04 Technische Universität München Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
CN102272148A (zh) * 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
US10568934B2 (en) * 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy

Also Published As

Publication number Publication date
DK3065761T3 (da) 2020-02-17
TWI729970B (zh) 2021-06-11
JP2016536369A (ja) 2016-11-24
US20150126458A1 (en) 2015-05-07
US20210008158A1 (en) 2021-01-14
EP3628324A1 (en) 2020-04-01
KR20160070164A (ko) 2016-06-17
EP3065761A1 (en) 2016-09-14
PT3065761T (pt) 2020-02-21
TW201609125A (zh) 2016-03-16
US20220175881A1 (en) 2022-06-09
WO2015069668A1 (en) 2015-05-14
JP2022107628A (ja) 2022-07-22
AU2020202968A1 (en) 2020-05-21
PL3065761T3 (pl) 2020-05-18
US20170157207A1 (en) 2017-06-08
EP3065761B1 (en) 2020-01-08
HUE047910T2 (hu) 2020-05-28
JP2020169191A (ja) 2020-10-15
CN105960247A (zh) 2016-09-21
CA2927012A1 (en) 2015-05-14
AU2014346921A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
ES2773317T3 (es) Método de tratamiento de estados del ojo con un DARPin anti-VEGF
ES2753135T3 (es) Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
JP6010528B2 (ja) Ｖｅｇｆ−ａレセプターの相互作用を阻害する改変結合タンパク質
ES2836948T3 (es) Proteínas de unión que inhiben la interacción del receptor de VEGF-A
ES2873379T3 (es) Proteína de fusión que comprende un dominio de unión a ligando de VEGF y PDGF
ES2349043T3 (es) Variantes de neublastina.
US20230054032A1 (en) Compositions and methods for treating ocular disease
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
EP4132540A2 (en) Bispecific aptamer compositions for the treatment of retinal disorders